{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:19:02Z","timestamp":1785161942474,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024J08304"],"award-info":[{"award-number":["2024J08304"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016808","name":"Natural Science Foundation of Xiamen Municipality","doi-asserted-by":"publisher","award":["3502Z202371048"],"award-info":[{"award-number":["3502Z202371048"]}],"id":[{"id":"10.13039\/100016808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00873-8","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:48:30Z","timestamp":1740746910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA Adverse Event Reporting System"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaoling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"3","key":"873_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2174\/157016307782109698","volume":"4","author":"ML Evangelista","year":"2007","unstructured":"Evangelista ML, Amadori S, Stasi R. Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use. Curr Drug Discov Technol. 2007;4(3):162.","journal-title":"Curr Drug Discov Technol"},{"issue":"23","key":"873_CR2","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, et al. American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829\u201366.","journal-title":"BLOOD ADV"},{"issue":"4","key":"873_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1053\/j.seminhematol.2019.09.001","volume":"56","author":"J Bussel","year":"2019","unstructured":"Bussel J, Kulasekararaj A, Cooper N, Verma A, Steidl U, Semple JW, Will B. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Semin Hematol. 2019;56(4):262\u201378.","journal-title":"SEMIN HEMATOL"},{"issue":"3","key":"873_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/bjh.18081","volume":"197","author":"H Al Samkari","year":"2022","unstructured":"Al Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, Vredenburg M, Cuker A. Adults with immune thrombocytopenia who switched to Avatrombopag following prior treatment with Eltrombopag or Romiplostim: A multicentre US study. Brit J Haematol. 2022;197(3):359\u201366.","journal-title":"BRIT J HAEMATOL"},{"key":"873_CR5","doi-asserted-by":"publisher","first-page":"704093","DOI":"10.3389\/fphar.2021.704093","volume":"12","author":"J Deng","year":"2021","unstructured":"Deng J, Hu H, Huang F, Huang C, Huang Q, Wang L, Wu A, Yang J, Qin D, Zou W, et al. Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: A systematic review and network Meta-analysis of randomized controlled trial. Front Pharmacol. 2021;12:704093.","journal-title":"FRONT PHARMACOL"},{"issue":"10","key":"873_CR6","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","volume":"113","author":"JB Bussel","year":"2009","unstructured":"Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with Romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161\u201371.","journal-title":"Blood"},{"issue":"3","key":"873_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","volume":"121","author":"MN Saleh","year":"2013","unstructured":"Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A, On BOTE, EXTEND SG. safety and efficacy of Eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537\u201345.","journal-title":"Blood"},{"issue":"8","key":"873_CR8","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","volume":"2","author":"JBD Bussel","year":"2015","unstructured":"Bussel JBD, de Miguel PGM, Despotovic JMD, Grainger JDM, Sevilla JM, Blanchette VSFC, Krishnamurti LM, Connor PM, David MM, Boayue KBM, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2(8):e315\u201325.","journal-title":"Lancet Haematol"},{"issue":"4","key":"873_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/bjh.18908","volume":"202","author":"MD Tarantino","year":"2023","unstructured":"Tarantino MD, Bussel JB, Lee EJ, Jamieson BD. A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of Avatrombopag versus Eltrombopag in ITP. Brit J Haematol. 2023;202(4):897\u20139.","journal-title":"BRIT J HAEMATOL"},{"issue":"204","key":"873_CR10","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1111\/bjh.19345","volume":"6","author":"MSCP Nichola Cooper","year":"2024","unstructured":"Nichola Cooper MSCP. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the united Kingdom: results from the TRAIT study. Brit J Haematol. 2024;6(204):2442\u201352.","journal-title":"BRIT J HAEMATOL"},{"key":"873_CR11","doi-asserted-by":"crossref","unstructured":"Toshiyuki Sakaeda ATKK. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 2013:796\u2013803.","DOI":"10.7150\/ijms.6048"},{"issue":"7\u20138","key":"873_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.drudis.2008.12.012","volume":"14","author":"M Hauben","year":"2009","unstructured":"Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14(7\u20138):343\u201357.","journal-title":"DRUG DISCOV TODAY"},{"key":"873_CR13","unstructured":"European Medicines Agency. Signal management\u2014designated medical events. 2024. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/signal-management#designated-medical-events-section. Accessed May 12,2024."},{"key":"873_CR14","doi-asserted-by":"crossref","unstructured":"Noguchi Y, Tachi T, Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform 2021;22(6).","DOI":"10.1093\/bib\/bbab347"},{"key":"873_CR15","unstructured":"David J, Kuter JBBR, Craig M, Kessler MASH, Jeff Rey S, Wasser SIHC, Francis J, Cuevas RSGD. Effi cacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. LANCET 2008."},{"issue":"5","key":"873_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1177\/0091270010372106","volume":"51","author":"JW Bauman","year":"2011","unstructured":"Bauman JW, Vincent CT, Peng B, Wire MB, Williams DD, Park JW. Effect of hepatic or renal impairment on Eltrombopag pharmacokinetics. J Clin Pharmacol. 2011;51(5):739\u201350.","journal-title":"J CLIN PHARMACOL"},{"key":"873_CR17","doi-asserted-by":"crossref","unstructured":"Danielle M, Townsley MDPS, Desmond MDBD, Valdez PAJL, Leuva MBBS, Katherine R. Calvo MDCE: Eltrombopag added to standard immunosuppression for aplastic Anemia. New Engl J Med 2017:1540\u201350.","DOI":"10.1056\/NEJMoa1613878"},{"issue":"7","key":"873_CR18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ajh.23225","volume":"87","author":"R Reid","year":"2012","unstructured":"Reid R, Bennett JM, Becker M, Chen Y, Milner L, Phillips IIGL, Liesveld J. Use of Eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia. Am J Hematol. 2012;87(7):743\u20135.","journal-title":"AM J HEMATOL"},{"key":"873_CR19","doi-asserted-by":"crossref","unstructured":"Raymond SM, Wong MNSA, Paul Burgess AJBB. Safety and efficacy of long-term treatment of chronic\/persistent ITP with Eltrombopag: final results of the EXTEND study. Blood 2017:2527\u201336.","DOI":"10.1182\/blood-2017-04-748707"},{"issue":"4","key":"873_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/FTD.0000000000000522","volume":"40","author":"M Marano","year":"2018","unstructured":"Marano M, Serafinelli J, Cairoli S, Martinelli D, Pisani M, Palumbo G, Cefalo MG, Cecchetti C, Di Nardo M, Falvella FS, et al. Eltrombopag-Induced acute liver failure in a pediatric patient: A Pharmacokinetic and Pharmacogenetic analysis. Ther Drug Monit. 2018;40(4):386\u20138.","journal-title":"THER DRUG MONIT"},{"key":"873_CR21","doi-asserted-by":"crossref","unstructured":"Hermann E, Ferdjallah A. Eltrombopag-induced Metabolic Acidosis and Hepatic Encephalopathy in Pediatric ITP. J Pediatr Hematol\/Oncol. 2022;44(2):e453.","DOI":"10.1097\/MPH.0000000000002300"},{"issue":"6","key":"873_CR22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1345\/aph.1P042","volume":"44","author":"SL Corman","year":"2010","unstructured":"Corman SL, Mohammad RA. Eltrombopag: A novel oral thrombopoietin receptor agonist. Annals Pharmacotherapy. 2010;44(6):1072\u20139.","journal-title":"Annals Pharmacotherapy"},{"issue":"6","key":"873_CR23","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1124\/dmd.110.037960","volume":"39","author":"K TAKEUCHI","year":"2011","unstructured":"Takeuchi K, Sugiura T, Umeda S, Matsubara K, Horikawa M, Nakamichi N, Silver DL, Ishiwata N. Pharmacokinetics and hepatic uptake of Eltrombopag, a novel Platelet-Increasing agent. Drug Metab Dispos. 2011;39(6):1088\u201396.","journal-title":"DRUG METAB DISPOS"},{"issue":"1","key":"873_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jha2.51","volume":"1","author":"K Ishiyama","year":"2020","unstructured":"Ishiyama K, Sato K, Imi T, Hosokawa K, Kondo Y, Sugimori N, Yamazaki H, Nakao S. Paroxysmal nocturnal hemoglobinuria-phenotype cells predict a good response to Eltrombopag in patients with refractory aplastic anemia. eJHaem. 2020;1(1):243\u20138.","journal-title":"eJHaem"},{"issue":"1","key":"873_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood.2019000940","volume":"136","author":"L Sun","year":"2020","unstructured":"Sun L, Babushok DV. Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood. 2020;136(1):36\u201349.","journal-title":"Blood"},{"issue":"7","key":"873_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.leukres.2004.12.009","volume":"29","author":"H Kakumitsu","year":"2005","unstructured":"Kakumitsu H, Kamezaki K, Shimoda K, Karube K, Haro T, Numata A, Shide K, Matsuda T, Oshima K, Harada M. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res. 2005;29(7):761\u20139.","journal-title":"Leuk RES"},{"issue":"6","key":"873_CR27","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1309\/09NP-3DFG-BLM9-E5LE","volume":"117","author":"VK Douglas","year":"2002","unstructured":"Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that May resemble chronic myeloproliferative disorders. Am J Clin Pathol. 2002;117(6):844\u201350.","journal-title":"AM J CLIN PATHOL"},{"key":"873_CR28","unstructured":"U.S. Food and Drug Administration. Promacta (Eltrombopag tablets). FDA oncologic drug advi-sory committee briefing document.http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4366b1-02-GSK.pdf.Accessed October 23,2008. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4366b1-02-GSK.pdf"},{"key":"873_CR29","doi-asserted-by":"crossref","unstructured":"James B, Bussel MDDJ. AMG 531, a Thrombopoiesis-Stimulating protein, for chronic ITP. N Engl J Med 2006.","DOI":"10.1056\/NEJMoa054626"},{"key":"873_CR30","doi-asserted-by":"crossref","unstructured":"James B, Bussel DJKV. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009.","DOI":"10.1182\/blood-2008-04-150078"},{"issue":"18","key":"873_CR31","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/blood-2009-05-224766","volume":"114","author":"DJ Kuter","year":"2009","unstructured":"Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with Romiplostim. Blood. 2009;114(18):3748\u201356.","journal-title":"Blood"},{"issue":"2","key":"873_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000452992","volume":"137","author":"RK Brynes","year":"2017","unstructured":"Brynes RK, Wong RSM, Thein MM, Bakshi KK, Burgess P, Theodore D, Orazi A. A 2-Year, longitudinal, prospective study of the effects of Eltrombopag on bone marrow in patients with chronic immune thrombocytopenia. Acta Haematol-Basel. 2017;137(2):66\u201372.","journal-title":"ACTA HAEMATOL-BASEL"},{"issue":"5","key":"873_CR33","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3324\/haematol.2013.098921","volume":"99","author":"W Ghanima","year":"2014","unstructured":"Ghanima W, Geyer JT, Lee CS, Boiocchi L, Imahiyerobo AA, Orazi A, Bussel JB. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica. 2014;99(5):937\u201344.","journal-title":"Haematologica"},{"issue":"9763","key":"873_CR34","first-page":"393","volume":"377","author":"GD Cheng","year":"2011","unstructured":"Cheng GD, Saleh MNM, Marcher CM, Vasey SM, Mayer BM, Aivado MM, Arning MM, Stone NLP, Bussel JBM. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet (British edition). 2011;377(9763):393\u2013402.","journal-title":"Lancet (British edition)"},{"key":"873_CR35","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.2147\/OTT.S333189","volume":"14","author":"Y Shen","year":"2021","unstructured":"Shen Y, Yu F, Ge H, Shao K, Zhou Y, Ye B, Shen Y, Wu D. First report of severe autoimmune hemolytic Anemia during Eltrombopag therapy in Waldenstrom Macroglobulinemia-Associated thrombocytopenia. Oncotargets Ther. 2021;14:5027\u201333.","journal-title":"ONCOTARGETS THER"},{"issue":"1","key":"873_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ajcp\/aqac130","volume":"159","author":"AD Jones","year":"2023","unstructured":"Jones AD, Sapatnekar S, Bakdash S. Drugs and conditions that May mimic hemolysis. Am J Clin Pathol. 2023;159(1):34\u201342.","journal-title":"AM J CLIN PATHOL"},{"issue":"2","key":"873_CR37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000508599","volume":"144","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, Goodarzi K. An Eltrombopag red (Plasma) alert. Acta Haematol-Basel. 2021;144(2):227\u20138.","journal-title":"ACTA HAEMATOL-BASEL"},{"issue":"10039","key":"873_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","volume":"388","author":"MD Tarantino","year":"2016","unstructured":"Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10039):45\u201354.","journal-title":"Lancet"},{"issue":"4","key":"873_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/lary.28970","volume":"131","author":"Y Abe","year":"2021","unstructured":"Abe Y, Toyama K, Kazurayama M, Tanaka S, Yamaizumi M, Ueno M, Spin JM, Hato N, Mogi M. Low-Normal platelets and decreasing platelets are risk factors for hearing impairment development. Laryngoscope. 2021;131(4):1\u20139.","journal-title":"Laryngoscope"},{"issue":"1","key":"873_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13104-019-4323-z","volume":"12","author":"SH Mohammed","year":"2019","unstructured":"Mohammed SH, Shab-Bidar S, Abuzerr S, Habtewold TD, Alizadeh S, Djafarian K. Association of anemia with sensorineural hearing loss: a systematic review and meta-analysis. Bmc Res Notes. 2019;12(1):2\u20136.","journal-title":"BMC RES NOTES"},{"issue":"5","key":"873_CR41","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/000348949710600506","volume":"106","author":"FAM Shaheen","year":"1997","unstructured":"Shaheen FAM, Mansuri NA, Sheikh IA, Al-Khader AA, Al-Shaikh AM, Huraib SO, Zazgornik J. Reversible uremic deafness: is it correlated with the degree of anemia? Annals Otology Rhinology Laryngology. 1997;106(5):391\u20133.","journal-title":"Annals Otology Rhinology Laryngology"},{"issue":"10","key":"873_CR42","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/10245332.2018.1478494","volume":"23","author":"MRR Lago","year":"2018","unstructured":"Lago MRR, Fernandes LDC, Lyra IM, Ramos RT, Teixeira R, Salles C, Ladeia AMT. Sensorineural hearing loss in children with sickle cell anemia and its association with endothelial dysfunction. Hematol (Luxembourg). 2018;23(10):849\u201355.","journal-title":"Hematol (Luxembourg)"},{"issue":"3","key":"873_CR43","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bjh.15573","volume":"183","author":"W Jurczak","year":"2018","unstructured":"Jurczak W, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, Allen LF. Phase 3 randomised study of Avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Brit J Haematol. 2018;183(3):479\u201390.","journal-title":"BRIT J HAEMATOL"},{"key":"873_CR44","first-page":"466","volume":"2018","author":"DJKL Allen","year":"2018","unstructured":"Allen DJKL. Avatrombopag, an oral thrombopoietin receptor agonist results of two double-blind, dose-rising, placebo-controlled phase 1 studies. Brit J Haematol. 2018;2018:183, 466\u201378.","journal-title":"BRIT J HAEMATOL"},{"key":"873_CR45","unstructured":"Dova Pharmaceuticals Inc. Doptelet: Prescribing information. 2019 (accessed on April 1, 2021). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210238s001lbl.pdf"},{"issue":"10","key":"873_CR46","first-page":"e47003","volume":"15","author":"RS Alesci","year":"2023","unstructured":"Alesci RS, Hecking C, Weissmann MV. Identification of an unmet medical need: height of depression, hypersomnia, and sleep apnea positively correlate with the level of fatigue in patients with immune thrombocytopenia. Cur\u0113us (Palo Alto CA). 2023;15(10):e47003.","journal-title":"Cur\u0113us (Palo Alto CA)"},{"issue":"ahead\u2013of\u2013print","key":"873_CR47","first-page":"1","volume":"ahead\u2013of\u2013print","author":"Q Fang","year":"2023","unstructured":"Fang Q, Huang F, Liang J, Chen Y, Li C, Zhang M, Wu X, Luo W. Safety of Romiplostim and Eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database. Expert Opin Drug Saf. 2023;ahead\u2013of\u2013print(ahead\u2013of\u2013print):1\u20138.","journal-title":"EXPERT OPIN DRUG SAF"},{"issue":"6","key":"873_CR48","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3109\/15563650.2013.811588","volume":"51","author":"D Seger","year":"2013","unstructured":"Seger D, Barker K, McNaughton C. Misuse of the Naranjo adverse drug reaction probability scale in toxicology. Clin Toxicol. 2013;51(6):461\u20136.","journal-title":"CLIN TOXICOL"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00873-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00873-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00873-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:48:37Z","timestamp":1740746917000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00873-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["873"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00873-8","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present pharmacovigilance study was conducted using a public database of spontaneous reports. Given the use of deidentified data, ethical approval was not considered necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}